Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 801–900 of 1,051

1. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
   on behalf of the European Conference on Infections in Leukemia (ECIL), Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiébaut, Anne Bergeron, Tomás Franquet, Nicole M. A. Blijlevens, Johan A. Maertens · 2019 · Leukemia
2. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer
   Xinglong Geng, Hongze Chen, Liang Zhao, Jisheng Hu, Wenbo Yang, Guanqun Li, Chundong Cheng, Zhongjie Zhao, Tao Zhang, Le Li et al. · 2021 · Frontiers in Cell and Developmental Biology
3. Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
   Nir Hacohen, Edward F. Fritsch, Todd A. Carter, Eric S. Lander, Catherine J. Wu · 2013 · Cancer Immunology Research
4. Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
   Yayi He, Christopher J. Rivard, Leslie M. Rozeboom, Hui Yu, Kim E. Ellison, Ashley A. Kowalewski, Caicun Zhou, Fred R. Hirsch · 2016 · Cancer Science
5. PD-1 expression on dendritic cells suppresses CD8⁺T cell function and antitumor immunity
   Lim, Tong Seng, Chew, Valerie, Sieow, Je Lin, Goh, Siting, Yeong, Joe Poh-Sheng, Soon, Ai Ling, Ricciardi-Castagnoli, Paola · 2016 · OncoImmunology
6. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas
   Sehui Kim, Moon‐Young Kim, Jaemoon Koh, Heounjeong Go, Dong Soo Lee, Yoon Kyung Jeon, Doo Hyun Chung · 2015 · European Journal of Cancer
7. Gastric Cancer: Basic Aspects
   Carlos Resende, Alexandra Thiel, José Carlos Machado, Ari P. Ristimaki · 2011 · Helicobacter
8. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
   Aaron J Franke, William Paul Skelton, Jason Scott Starr, Hiral D. Parekh, James J. Lee, Michael James Overman, Carmen Joseph Allegra, Thomas J. George · 2019 · JNCI Journal of the National Cancer Institute
9. A comprehensive review of immune checkpoint inhibitors for cancer treatment
   Md Aslam Hossain · 2024 · International Immunopharmacology
10. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
    Karishma R. Rajani, Christopher Parrish, Timothy J. Kottke, Jill Thompson, Shane Zaidi, Elizabeth J. Ilett, Kevin G. Shim, Rosa María Díaz, Hardev Pandha, Kevin Joseph Harrington et al. · 2015 · Molecular Therapy
11. Immunology beats cancer: a blueprint for successful translation
    Drew M. Pardoll · 2012 · Nature Immunology
12. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
    Kazuki Takada, Tatsuro Okamoto, Fumihiro Shoji, Mototsugu Shimokawa, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Yuzo Suzuki, Takatoshi Fujishita, Gouji Toyokawa et al. · 2016 · Journal of Thoracic Oncology
13. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
    Francesco Massari, Matteo Santoni, Chiara Ciccarese, Daniele Santini, Salvatore Alfieri, Guido Martignoni, Matteo Brunelli, Francesco Piva, Rossana Berardi, Rodolfo Montironi et al. · 2015 · Cancer Treatment Reviews
14. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
    Taisuke Yagi, Yoshifumi Baba, Takatsugu Ishimoto, Masaaki Iwatsuki, Yuji Miyamoto, Naoya Yoshida, Masayuki Watanabe, Hideo Baba · 2017 · Annals of Surgery
15. Breaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics
    Wenpei Fan, Wei Tang, Joseph Lau, Zheyu Shen, Jin Xie, Jianlin Shi, Xiaoyuan Shawn Chen · 2019 · Advanced Materials
16. Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
    Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda K. Psyrri · 2019 · Frontiers in Oncology
17. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
    Xiaoxiao Peng, Ruoying Yu, Xue Wu, Shuyu Wu, Can Pi, Zhihong Chen, Xu‐Chao Zhang, Cun-Yi Gao, Yang Washington Shao, Li Liu et al. · 2020 · Journal for ImmunoTherapy of Cancer
18. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Ajjai Shivaram Alva, Pam K. Mangat, Elizabeth S. Garrett-Mayer, Susan Halabi, Damien Mikael Hansra, Carmen Julia Calfa, Maged F. Khalil, Eugene R. Ahn, Timothy Lewis Cannon, Pamela Ann Crilley et al. · 2021 · Journal of Clinical Oncology
19. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
    Ruf, Melanie, Moch, Holger, Schraml, Peter · 2016 · International Journal of Cancer
20. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
    Su‐Jin Shin, Yoon Kyung Jeon, Pil-Jong Kim, Yong Mee Cho, Jaemoon Koh, Doo Hyun Chung, Heounjeong Go · 2015 · Annals of Surgical Oncology
21. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
    Jill J. Bastman, Hilary S. Serracino, Yuwen Zhu, Michelle R. Koenig, Valerica Mateescu, Sharon B. Sams, Kurtis D. Davies, Christopher D. Raeburn, Robert C. McIntyre, Bryan R. Haugen et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism
22. CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State
    Matthew David Martin, Vladimir P. Badovinac, Thomas S. Griffith · 2020 · Frontiers in Immunology
23. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
    David, Justin M., Dominguez, Charli, McCampbell, Kristen K., Gulley, James L., Schlom, Jeffrey, Palena, Claudia · 2017 · OncoImmunology
24. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
    Takeo Fujii, Rivka R. Colen, Mehmet Asım Bilen, Kenneth R. Hess, Joud Hajjar, Maria Eugenia Suarez-Almazor, Anas Alshawa, David S. Hong, Apostolia Maria Tsimberidou, Filip Jankú et al. · 2017 · Investigational New Drugs
25. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
    Blake M. Warner, Alan N. Baer, Evan J. Lipson, Clint Tanner Allen, Christian S. Hinrichs, Arun Rajan, Eileen Pelayo, Margaret E. Beach, James L. Gulley, Ravi Amrit Madan et al. · 2019 · The Oncologist
26. Mechanisms of immune escape in the cancer immune cycle
    Sha Tang, Qian Ning, Ling Yang, Zhongcheng Mo, Shengsong Tang · 2020 · International Immunopharmacology
27. Emerging targeted agents in metastatic breast cancer
    Dimitrios Zardavas, Jose M Baselga, Martine J Piccart · 2013 · Nature Reviews Clinical Oncology
28. Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
    Vamsidhar Velcheti, David L. Rimm, Kurt Alex Schalper · 2013 · Journal of Thoracic Oncology
29. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
    Liang Wang, Hua Wang, Hao Chen, Wei-da Wang, Xiao-qin Chen, Qi-rong Geng, Zhong-Jun Xia, Yue Lu · 2015 · Oncotarget
30. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
    Derya Kabacaoğlu, Katrin J. Ciecielski, Dietrich Alexander Ruess, Hana Algül · 2018 · Frontiers in Immunology
31. Arginase 1 is a key driver of immune suppression in pancreatic cancer
    Rosa Elena Menjivar, Zeribe C. Nwosu, Wenting Du, Katelyn L. Donahue, Hanna S. Hong, Carlos E. Espinoza, Kristee L. Brown, Ashley Velez-Delgado, Wei Yan, Fatima Lima et al. · 2023 · eLife
32. Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
    Miguel F. Sanmamed, Lieping Chen · 2014 · The Cancer Journal
33. Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
    Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Kazuhiko Yamada, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Masayoshi Kage, Tomoaki Hoshino · 2014 · Journal of Thoracic Oncology
34. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
    Lei Lü, Xiaobing Xu, Bin Zhang, Rongsheng Zhang, Hongzan Ji, Xuan Wang · 2014 · Journal of Translational Medicine
35. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
    Ziming Du, Malak Abedalthagafi, Ayal Aaron Aizer, Allison McHenry, Heather H. Sun, Mark‐Anthony Bray, Omar Viramontes, Revaz Machaidze, Priscilla Kaliopi Brastianos, David A. Reardon et al. · 2014 · Oncotarget
36. Immunotherapy advances for glioblastoma
    D. A. Reardon, Gordon James Freeman, Catherine J. Wu, Ennio Antonio Chiocca, Kai W. Wucherpfennig, Patrick Yung Wen, Edward F. Fritsch, William T. Curry, John Howard Sampson, Glenn Dranoff · 2014 · Neuro-Oncology
37. Impact of sepsis on CD4 T cell immunity
    Javier Cabrera-Pérez, Stephanie A. Condotta, Vladimir P. Badovinac, Thomas S. Griffith · 2014 · Journal of Leukocyte Biology
38. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer
    Seiichi Ikeda, Tatsuro Okamoto, Shinji Okano, Yuichiro Umemoto, Tetsuzo Tagawa, Yosuke Morodomi, Mikihiro Kohno, Shinichiro Shimamatsu, Hirokazu Kitahara, Yuzo Suzuki et al. · 2016 · Journal of Thoracic Oncology
39. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
    Jacqueline Fontugne, Jérémy Augustin, Anaïs Pujals, Philippe Compagnon, Benoı̂t Rousseau, Alain Luciani, Christophe Tournigand, Daniel Cherqui, Daniel Azoulay, Jean–Michel Pawlotsky et al. · 2017 · Oncotarget
40. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner
    Zhang, Qian-Feng, Li, Jia, Jiang, Kuo, Wang, Rui, Ge, Jun-li, Yang, Hong, Liu, Shu-Juan, Jia, Lin-Tao, Wang, Lei, Chen, Bi-Liang · 2020 · Theranostics
41. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
    Susan Heavey, Kenneth John O'Byrne, Kathy A. Gately · 2013 · Cancer Treatment Reviews
42. PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
    Alexander W. Macfarlane, Mowafaq Jillab, Elizabeth R. Plimack, Gary R. Hudes, Robert G. Uzzo, Samuel Litwin, Essel Dulaimi, Tahseen Al‐Saleem, Kerry S. Campbell · 2013 · Cancer Immunology Research
43. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
    Chunwan Lu, Asif M. Talukder, Natasha M. Savage, Nagendra Singh, Kebin Liu · 2017 · OncoImmunology
44. Introduction to checkpoint inhibitors and cancer immunotherapy
    Arlene H. Sharpe · 2017 · Immunological Reviews
45. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer
    Yu Pan, Fengchun Lu, Qinglin Fei, Xingxing Yu, Ping Xiong, Xunbin Yu, Yuan Dang, Zelin Hou, Wenji Lin, Xianchao Lin et al. · 2019 · Journal of Hematology & Oncology
46. Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
    Zili Gu, Candido G. Da Silva, Koen van der Maaden, FERRY A. OSSENDORP, Luis Javier Cruz · 2020 · Pharmaceutics
47. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
    Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher M. Attwood, Sebastiano Battaglia, Saby George, Gurkamal S. Chatta, Igor J. Puzanov et al. · 2021 · Nature Communications
48. Cutaneous adverse effects of targeted therapies
    James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia Mucci LoRusso, Aleksandar Sekulić · 2015 · Journal of the American Academy of Dermatology
49. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
    T. Greten, Xin-Wei Wang, F. Korangy · 2015 · Gut
50. Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
    Ignacio Melero, Daniel Hirschhorn-Cymerman, Aizea Morales‐Kastresana, Miguel F. Sanmamed, Jedd D. Wolchok · 2013 · Clinical Cancer Research
51. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
    Takeru Asano, Yusuke Meguri, Takanori Yoshioka, Yuriko Kishi, Miki Iwamoto, Makoto Nakamura, Yasuhisa Sando, Hideo Yagita∥, John Koreth, Haesook T. Kim et al. · 2017 · Blood
52. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
    Samantha R. Ellis, Aren T Vierra, Jillian Wong Millsop, Mario E. Lacouture, Maija H. Kiuru · 2020 · Journal of the American Academy of Dermatology
53. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
    Takashi Inozume, Tomonori Yaguchi, Junpei Furuta, Kazutoshi Harada, Yutaka Kawakami, Shinji Shimada · 2015 · Journal of Investigative Dermatology
54. Prognostic significance of PD-L1 in solid tumor
    Qianqian Wang, Fang Liu, Lei Liu · 2017 · Medicine
55. Systemic treatment of renal cell cancer: A comprehensive review
    Amparo Sánchez-Gastaldo, Emmanuelle Kempf, Aranzazu González del Alba, Ignacio Durán · 2017 · Cancer Treatment Reviews
56. Development of immune checkpoint therapy for cancer
    Jill M. Fritz, Michael J. Lenardo · 2019 · The Journal of Experimental Medicine
57. Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection
    Katrin D. Mayer-Barber, Daniel L. Barber · 2015 · Cold Spring Harbor Perspectives in Medicine
58. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
    Thomas Köhnke, Christina Krupka, Johanna Tischer, Thomas Knösel, Marion S. Subklewe · 2015 · Journal of Hematology & Oncology
59. Survival of patients with advanced metastatic melanoma: The impact of novel therapies
    Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Keith T. Flaherty, Jean‐Jacques Grob, Axel Hauschild, James Larkin, Georgina Venetia Long, Paul C. Lorigan, Grant A. McArthur et al. · 2015 · European Journal of Cancer
60. The role of neoantigens in response to immune checkpoint blockade
    Nadeem Riaz, Luc G.T. Morris, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Timothy An-thy Chan · 2016 · International Immunology
61. Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy
    Neha Kamran, Padma Kadiyala, Meghna Saxena, Marianela Candolfi, Youping Li, Mariela A. Moreno-Ayala, Nicholas Saleem Raja, Diana Shah, Pedro Ricardo Lowenstein, Maria Graciela Castro · 2017 · Molecular Therapy
62. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
    Hisato Kawakami, Junko Tanizaki, Kaoru Tanaka, Koji Haratani, Hidetoshi Hayashi, Masayuki Takeda, Ken Kamata, Mamoru Takenaka, Masatomo Kimura, Takaaki Chikugo et al. · 2017 · Investigational New Drugs
63. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
    Piao Li, Tingting Huang, Qi Zou, Dian Liu, Yihua Wang, Ximin Tan, Wei Yao, Hong Qiu · 2019 · The Journal of Immunology
64. Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
    Mingjie Zhang, Li-Feng Huang, Guoping Ding, Huilian Huang, Guoliang Cao, Xu Dong Sun, Neng Lou, Qiang Wei, Tao Shen, Xiaodong Xu et al. · 2020 · Journal for ImmunoTherapy of Cancer
65. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
    Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
66. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model
    Wang, Lei, Amoozgar, Zohreh, Huang, Jing, Saleh, Mohammad H., Xing, Deyin, Orsulic, Sandra, Goldberg, Michael S. · 2015 · Cancer Immunology Research
67. Genetic evolution of T-cell resistance in the course of melanoma progression
    Sucker, Antje, Zhao, Fang, Real, Birgit, Heeke, Christina, Bielefeld, Nicola, Maβen, Stefan, Horn, Susanne, Moll, Iris, Maltaner, Raffaela, Horn, Peter A. et al. · 2014 · Clinical Cancer Research
68. Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway
    Xu, Xinjian, Lv, Ji, Guo, Fang, Li, Jing, Jia, Yitao, Jiang, Da, Wang, Na, Zhang, Chao, Kong, Lingyu, Liu, Yabin et al. · 2020 · Frontiers in Microbiology
69. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
    Michael John Fuller, Benoît Callendret, Baogong Zhu, Gordon James Freeman, Dana L. Hasselschwert, William C. Satterfield, Arlene H. Sharpe, Lynn B. Dustin, Charles M. Rice, Arash Grakoui et al. · 2013 · Proceedings of the National Academy of Sciences
70. Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
    Ann L. White, H.T. Claude Chan, Ruth R. French, Jane E. Willoughby, Christopher Ian Mockridge, Ali Roghanian, Christine A. Penfold, Steven G. Booth, Ali Dodhy, Marta Ewa Polak et al. · 2014 · Cancer Cell
71. Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
    Pei Y. Teo, Chuan He Yang, Lynsey May Whilding, Ana C. Parente‐Pereira, John F. Maher, Andrew J.T. George, James L. Hedrick, Yi Yan Yang, Sadaf Ghaem‐Maghami · 2015 · Advanced Healthcare Materials
72. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
    Kostandinos Sideras, Henri Braat, Jaap Kwekkeboom, Casper H.J. van Eijck, Maikel Petrus Peppelenbosch, Stefan Sleijfer, Marco J. Bruno · 2013 · Cancer Treatment Reviews
73. Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
    Robert Louis Ferris, Binfeng Lu, Larry Kane · 2014 · The Journal of Immunology
74. Impaired B‐cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies
    Eric Meffre, Kevin C. O’Connor · 2019 · Immunological Reviews
75. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
    Leisha A. Emens · 2012 · Expert Review of Anticancer Therapy
76. Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?
    Xavier Sagaert, Arno Vanstapel, Sanne Verbeek · 2018 · Pathobiology
77. Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
    Michael D. Arensman, Xiaoran S. Yang, Danielle Leahy, Lourdes Toral‐Barza, Mary Mileski, Edward C. Rosfjord, Fang Wang, Shibing Deng, Jeremy S. Myers, Robert T. Abraham et al. · 2019 · Proceedings of the National Academy of Sciences
78. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
    Miguel F. Sanmamed, Inmaculada Rodríguez, Kurt Alex Schalper, Carmen Oñate, Arantza Azpilikueta, Maria Esperanza Rodriguez-Ruiz, Aizea Morales‐Kastresana, Sara Labiano, José Luis Perez‐Gracia, Salvador Martín‐Algarra et al. · 2015 · Cancer Research
79. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
    Barbara Merelli, Daniela Massi, Laura Cattaneo, Mario Mandalà · 2013 · Critical Reviews in Oncology/Hematology
80. Mechanisms of action of therapeutic antibodies for cancer
    Jason Mark Redman, Elizabeth Hill, Dalal S. Aldeghaither, Louis M. Weiner · 2015 · Molecular Immunology
81. Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases
    Steven C. Katz, Zubin M. Bamboat, Ajay V. Maker, Jinru Shia, Venu Gopal Pillarisetty, Adam Charles Yopp, Cyrus V. Hedvat, Mithat Gönen, William R. Jarnagin, Yuman Fong et al. · 2012 · Annals of Surgical Oncology
82. PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
    Enrico Munari, Giuseppe Zamboni, Gianluigi Lunardi, Luigi Marchionni, Marcella Marconi, Marco Sommaggio, Matteo Brunelli, Guido Martignoni, George Jabboure Netto, Mohammad Obaidul Hoque et al. · 2018 · Journal of Thoracic Oncology
83. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy
    Zhaoting Li, Yixin Wang, Yuexin Shen, Chenggen Qian, David Oupický, Minjie Sun · 2020 · Science Advances
84. HIV and co‐infections
    Christina C. Chang, Megan Crane, Jingling Zhou, Michael Mina, Jeffrey John Post, Barbara Cameron, Andrew R. Lloyd, Anthony Jaworowski, Martyn A. French, Sharon R. Lewin · 2013 · Immunological Reviews
85. Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
    Alyssa K. Kosmides, John-William Sidhom, Andrew K. Fraser, Catherine Ami Bessell, Jonathan P. Schneck · 2017 · ACS Nano
86. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
    Siwei Zheng, Wenwen Wang, Lesang Shen, Yao Yao, Wen-Jie Xia, Chao Ni · 2024 · Experimental Hematology & Oncology
87. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status
    Messai, Yosra, Gad, Sophie, Noman, Muhammad Zaeem, Le Teuff, Gwenael, Couve, Sophie, Janji, Bassam, Kammerer, Solenne Florence, Rioux-Leclerc, Nathalie, Hasmim, Meriem, Ferlicot, Sophie et al. · 2016 · European Urology
88. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer
    Valeria Quaranta, Carolyn Rainer, Sebastian Rune Nielsen, Meirion Raymant, Muhammad S. Ahmed, Dannielle D. Engle, Arthur Taylor, Trish Murray, Fiona Campbell, Daniel H. Palmer et al. · 2018 · Cancer Research
89. Nivolumab for the treatment of hepatocellular carcinoma
    Fabian Finkelmeier, Oliver Waidmann, Joerg Trojan · 2018 · Expert Review of Anticancer Therapy
90. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors
    Cramer, Peyton, Bresalier, Robert S. · 2017 · Current Gastroenterology Reports
91. Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events
    Jennifer Kwak, Sree Harsha Tirumani, Annick D. Van den Abbeele, Phillip J. Koo, Heather A. Jacene · 2015 · Radiographics
92. Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned
    Joe Yujiao Chang, Andrea Bezjak, F. Mornex · 2014 · Journal of Thoracic Oncology
93. Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
    James N. Arnold, Łukasz Magiera, Matthew Kraman, Douglas T. Fearon · 2013 · Cancer Immunology Research
94. STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells
    James W Austin, Peiyuan Lu, Parimal Majumder, Rafi Ahmed, Jeremy M. Boss · 2014 · The Journal of Immunology
95. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
    Aaron M. Udager, Ting‐yu Liu, Stephanie L. Skala, Martin J. Magers, Andrew S. McDaniel, Daniel Eidelberg Spratt, Felix Yi-Chung Feng, Javed Siddiqui, Xuhong Cao, Kristina L. Fields et al. · 2016 · Annals of Oncology
96. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung
    Sehui Kim, Jaemoon Koh, Moon‐Young Kim, Dohee Kwon, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung · 2016 · Human Pathology
97. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling
    Maria I Toki, Christopher R. Merritt, Pok Fai Wong, James William Smithy, Harriet M. Kluger, Konstantinos Nikolaos Syrigos, Giang T. Ong, Sarah E. Warren, Joseph Beechem, David L. Rimm · 2019 · Clinical Cancer Research
98. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
    Jian Wang, hao-Ting sun, Q. Zeng, Xue-Jun Guo, Hui Wang, Huan Liu, Zhong-Yi Dong · 2019 · Scientific Reports
99. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
    John Stagg, Bertrand Allard · 2013 · Therapeutic Advances in Medical Oncology
100. Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
     Chrisann Kyi, Michael Andrew Postow · 2016 · Immunotherapy